Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Concin

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Cell Death and Differentiation|September 5, 2018
Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|December 28, 2016
L1CAM in the Early Enteric and Urogenital SystemElisabeth Judith Pechriggl, Nicole Concin, Michael J Blumer, et al.
Contraception|March 10, 2012
Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine systemBeata Seeber, Stephanie C Ziehr, Andreas Gschlieβer, et al.
International Journal of Cancer|January 27, 2009
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancerAlain G Zeimet, Daniel Reimer, Dominik Wolf, et al.
Cancer Immunology, Immunotherapy : CII|August 19, 2010
Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancerAlain G Zeimet, Daniel Reimer, Lukas Schwentner, et al.
ESMO Open|November 26, 2020
Implementing clinical practice guidelines: time to assess itCristiana Sessa, Nicoletta Colombo, Carien L Creutzberg, et al.
Obstetrics and Gynecology|May 24, 2012
Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancerStephan Polterauer, Susan Khalil, Oliver Zivanovic, et al.
Cancers|April 12, 2022
Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation StudyRafał Watrowski, Eva Obermayr, Christine Wallisch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2020
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device developmentNicole Concin, Isabelle Ray-Coquard, Rosalind M Glasspool, et al.
Cancer Research|April 3, 2004
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivoNicole Concin, Kirsten Becker, Neda Slade, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Cell Death and Differentiation|September 5, 2018
Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|December 28, 2016
L1CAM in the Early Enteric and Urogenital SystemElisabeth Judith Pechriggl, Nicole Concin, Michael J Blumer, et al.
Contraception|March 10, 2012
Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine systemBeata Seeber, Stephanie C Ziehr, Andreas Gschlieβer, et al.
International Journal of Cancer|January 27, 2009
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancerAlain G Zeimet, Daniel Reimer, Dominik Wolf, et al.
Cancer Immunology, Immunotherapy : CII|August 19, 2010
Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancerAlain G Zeimet, Daniel Reimer, Lukas Schwentner, et al.
ESMO Open|November 26, 2020
Implementing clinical practice guidelines: time to assess itCristiana Sessa, Nicoletta Colombo, Carien L Creutzberg, et al.
Obstetrics and Gynecology|May 24, 2012
Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancerStephan Polterauer, Susan Khalil, Oliver Zivanovic, et al.
Cancers|April 12, 2022
Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation StudyRafał Watrowski, Eva Obermayr, Christine Wallisch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2020
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device developmentNicole Concin, Isabelle Ray-Coquard, Rosalind M Glasspool, et al.
Cancer Research|April 3, 2004
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivoNicole Concin, Kirsten Becker, Neda Slade, et al.
Pageof 14